

Addendum:

Additional description of the updated costs used in the manufacturer's submission

Following concerns raised by the ERG regarding the calculation of the average cost per patient, the manufacturer revised the methodology used to estimate the acquisition cost of the drug. Patient-level data from the STS 201 trial were used to calculate the average number of 1mg and 0.25mg vials used per patient and the proportion of patients receiving trabectedin in each cycle. This equated to a cost per patient of £23,719 (excluding administration costs) and £25,986 when administration costs and a pre-treatment injection of dexamethasone were included.

Erratum

After issuing the ERG report the following errors were found:

- Table 5, p 45, section 5.3: The table was a reproduction of the MS (Table 11 page 11, response of the 24 April 2009) but did not correspond to the results presented in the final excel model.

Results from the model are presented below:

Table 5 from ERG report: Net benefit analysis (base case analysis)

	<i>Willingness to pay = £20,000</i>		<i>Willingness to pay = £30,000</i>		<i>Willingness to pay = £40,000</i>	
	<i>ENB</i>	<i>P (CE)</i>	<i>ENB</i>	<i>P (CE)</i>	<i>ENB</i>	<i>P (CE)</i>
Trabectedin	- 11,428	-	-3,364	-	4,700	0.003
BSC	5,702	1.000	9,106	1.000	12,509	0.997

ENB = Expected Net Benefit P(CE) denotes the probability of cost effectiveness

- Table 6, p 46, section 5.3: The table reported in the ERG report was a reproduction of the Table 11, page 11 of the MS (response of the 24 April 2009). The Table should have been a reproduction of the Table 15, page 14 of the MS (response of the 24 April 2009).

Table 6 from ERG report: Net benefit analysis (Pooled analysis)¹

	<i>Willingness to pay = £20,000</i>		<i>Willingness to pay = £30,000</i>		<i>Willingness to pay = £40,000</i>	
	<i>ENB</i>	<i>P (CE)</i>	<i>ENB</i>	<i>P (CE)</i>	<i>ENB</i>	<i>P (CE)</i>
<i>Trabectedin</i>	-£3,847.93	0.000	£2,859	0	£9,567	0.088
<i>BSC</i>	£5,749.20	1.000	£9,189	1	£12,628	0.912

ENB = Expected Net Benefit P(CE) denotes the probability of cost effectiveness

¹ Before correction of errors found by the ERG in the Excel model